Four years ago, we started Orchestra Bio to help biotech and pharma teams advance their drug development programs. Developing medicines is incredibly complex, spanning thousands of decisions and dependencies across discovery, preclinical, manufacturing, and clinical.

AI has now reached an inflection point where people and agents can take this on together. Agents can handle planning, orchestration, and analysis, while scientists and program leaders focus on the decisions that require their expertise.

Today, we’re thrilled to share that Orchestra Bio is joining OpenAI to continue our mission at an even greater scale. Read more about what’s next here.

Thank you to all our customers, investors, and supporters for believing in us.